Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Laboratory of Hepatology, CHROMETA, KU Leuven, Leuven, Belgium.
Sci Rep. 2024 Nov 2;14(1):26465. doi: 10.1038/s41598-024-78119-6.
The role of immunosuppressive therapy on SARS-CoV-2 infection risk and COVID-19 severity remains unclear in unvaccinated solid organ transplant recipients. We included 1957 organ transplant recipients between July 2020 and April 2021 to analyze whether baseline immunosuppressive therapy and other risk factors are associated with SARS-CoV-2 infection and severe COVID-19. In total, 247 (12.6%) had SARS-CoV-2 (defined as positive nasopharyngeal swab and/or positive antibody titer). Of these, 57 (23.1%) had severe COVID-19, defined as oxygen supplementation, intensive care unit admission or death. Multivariable analysis identified diabetes (hazard ratio (HR) 1.39 (95% confidence interval (CI) 1.05-1.83)), chronic lung disease (HR 1.71 (95% CI 1.13-2.60)) and contact with a COVID-19 positive individual (HR 3.61 (95% CI 2.61-4.99) as independent risk factors for SARS-CoV-2 infection. There was no association between immunosuppressive therapy and infection risk. Severe COVID-19 was multivariably associated with hypertension (OR 5.45 (95% CI 1.66-17.84)), chronic kidney disease (OR 3.55 (95% CI 1.75-7.19)), corticosteroid use (OR 2.93 (95% CI 1.03-2.55)) and having a COVID-19 positive housemate (OR 6.77 (95% CI 2.65-17.28)). In conclusion, baseline corticosteroid use, but no other immunosuppressive agent, is independently associated with severe COVID-19 in unvaccinated SOT recipients after correction for hypertension, chronic kidney disease, housemates affected by COVID-19 and transplant type.
在未接种疫苗的实体器官移植受者中,免疫抑制治疗对 SARS-CoV-2 感染风险和 COVID-19 严重程度的作用仍不清楚。我们纳入了 1957 名 2020 年 7 月至 2021 年 4 月期间的器官移植受者,以分析基线免疫抑制治疗和其他危险因素是否与 SARS-CoV-2 感染和严重 COVID-19 相关。共有 247 名(12.6%)受者 SARS-CoV-2 检测呈阳性(定义为鼻咽拭子检测呈阳性和/或抗体滴度阳性)。其中,57 名(23.1%)受者患有严重 COVID-19,定义为需要吸氧、入住重症监护病房或死亡。多变量分析确定糖尿病(风险比(HR)1.39(95%置信区间(CI)1.05-1.83))、慢性肺部疾病(HR 1.71(95% CI 1.13-2.60))和与 COVID-19 阳性个体接触(HR 3.61(95% CI 2.61-4.99))是 SARS-CoV-2 感染的独立危险因素。免疫抑制治疗与感染风险之间没有关联。严重 COVID-19 与高血压(OR 5.45(95% CI 1.66-17.84))、慢性肾脏病(OR 3.55(95% CI 1.75-7.19))、皮质类固醇使用(OR 2.93(95% CI 1.03-2.55))和与 COVID-19 阳性室友同住(OR 6.77(95% CI 2.65-17.28))显著相关。总之,在调整高血压、慢性肾脏病、受 COVID-19 影响的室友和移植类型后,未接种疫苗的 SOT 受者中,基线皮质类固醇的使用,而不是其他免疫抑制剂,与严重 COVID-19 独立相关。